This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Outlook Quality of Life Intervention (NCT00784095), a randomized na study. The primary outcome is Quality of Life - Preparation.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT00784095 |
| Phase | NA |
| Condition | Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 36 |
| Arms in the primary outcome | n/a |
| Lead sponsor | VA Office of Research and Development |
| Results posted | Yes |
2. Clinical Question
The study asks whether discussions about life completion and preparation are associated with changes in quality of life for people living with serious illness. Its stated purpose refers to conversations about life story, forgiveness, and future goals. The primary measure is the preparation sub-scale of the Quality Of Life At The End Of Life measure, recorded at baseline and at 6 and 8 week follow-up.
Population
People with cancer, congestive heart failure, or chronic obstructive pulmonary disease. The registry record does not report further eligibility details in the primary-outcome description.
Intervention
Preparation and completion discussions with a facilitator. The record describes three meetings lasting forty-five minutes to one hour and identifies life review as a topic in the first session. The detailed description of later sessions is incomplete in the registry record.
Comparator
The randomized groups were preparation and completion, attention control, and true control. The attention-control group listened to a non-guided relaxation CD with a facilitator; the true-control group received no intervention or attention control.
Primary question
How did preparation sub-scale scores change across the listed assessment times, and how did those scores compare among the randomized groups? A single comparison and its result are not reported in the registry record.
This distinction matters: the registry describes the question and planned measurement schedule, but it does not supply an estimate of the intervention-group difference. The posted information therefore supports an account of the trial question, not a conclusion about the size or direction of any observed effect.
3. Trial Design
This was a randomized, parallel-group trial with three groups and no masking recorded. The registry lists an enrollment of 36. The groups were Preparation and Completion, Attention Control, and True Control. The adverse-event record lists 12 participants at risk in each group, but that information alone does not describe the analysis population for the quality-of-life endpoint.
The Preparation and Completion group met with a facilitator three times for forty-five minutes to one hour to discuss life completion and preparation. The first session included life review. The registry’s description of this group ends before the details of later sessions are complete, so those details are not reported in the registry record. The stated overall purpose also refers to life story, forgiveness, and future goals.
The Attention Control group met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD. The True Control group received neither an intervention nor attention control. These groups represent different comparisons: preparation and completion versus attention, preparation and completion versus no intervention, and attention versus no intervention. The registry does not identify one of these as the sole primary contrast.
The study status is completed. The record lists a start in 2008-12 and primary completion in 2009-05. The trial’s phase is listed as NA. Whether the study used additional stratification, concealment procedures, or other allocation safeguards is not reported in the registry record. Randomization can reduce systematic differences between groups on average, but it does not guarantee that groups are alike in a small trial, and the posted information does not give baseline group characteristics for judging that question.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Preparation and Completion | Attention Control | True Control |
|---|---|---|---|
| STARTED | 12 | 12 | 12 |
| COMPLETED | 12 | 11 | 11 |
| NOT COMPLETED | 0 | 1 | 1 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Preparation and Completion | Attention Control | True Control | Total |
|---|---|---|---|---|---|
| Participants analysed | 12 | 12 | 12 | 36 | |
| Age, Continuous | years | 64 (SD 10) | 68 (SD 10) | 69 (SD 14) | 67 (SD 11) |
| Sex: Female, Male: Female | Participants | 0 | 1 | 0 | 1 |
| Sex: Female, Male: Male | Participants | 12 | 11 | 12 | 35 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 5 | 5 | 4 | 14 |
| Race (NIH/OMB): White | Participants | 7 | 5 | 5 | 17 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 2 | 3 | 5 |
| Region of Enrollment: United States | participants | 12 | 12 | 12 | 36 |
6. Primary Endpoint
The registry lists the primary outcome as Quality of Life - Preparation, measured over Baseline, 6 and 8 week follow up.
| Element | Registry entry |
|---|---|
| Result type | Mean |
| Measure of spread | Standard Deviation |
| Unit | units on a scale |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is the Quality Of Life At The End Of Life preparation sub-scale. The registry describes the parent QUAL-E 2009 measure as a 31 item assessment covering life completion, relationships with health care providers, preparation for death, physical symptoms, and affective social support. The primary sub-scale contains 4 items. Each item is scaled from 1 to 5, and the sub-scale has a stated minimum of 5 and maximum of 20. Higher scores indicate better preparation.
This endpoint focuses on preparation rather than every aspect of quality of life covered by the parent measure. It is relevant to the intervention’s stated aim because the intervention discusses life completion and preparation. The registry identifies a mean and standard deviation as the summary approach and lists assessment at baseline, 6 and 8 week follow-up.
Repeated assessment can describe scores over time, but the meaning of a change depends on the comparison being made and the analysis used. A within-group change is not, by itself, evidence that the intervention caused that change; comparisons among randomized groups are needed to account for changes that might also occur without the intervention. The registry record does not report a primary-outcome estimate, its uncertainty, or a single selected comparison.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies the primary outcome and assessment schedule but does not report the result needed to estimate an effect on preparation scores. It gives no group means or standard deviations for the primary endpoint, no between-group estimate, and no confidence interval or p-value for a primary comparison. Accordingly, the magnitude, direction, and precision of any difference in preparation scores are not reported in the registry record.
The endpoint is assessed at baseline and at 6 and 8 week follow-up, so several possible contrasts could be relevant: change from baseline within a group, differences between groups at a follow-up, or differences in change over time between groups. Those quantities answer different questions. A follow-up group difference can reflect both baseline differences and subsequent change, while a difference in change directly compares the groups’ trajectories. The registry record does not specify which estimand or contrast was used for the primary analysis.
The three-group design also makes the choice of comparator important. Preparation and Completion versus Attention Control asks about the intervention relative to facilitator contact and a relaxation activity. Preparation and Completion versus True Control compares the intervention with no intervention or attention control. Attention Control versus True Control addresses the effect of the attention-control condition relative to no intervention. No single comparison is selected in the posted primary-outcome information.
In general, a confidence interval describes the range of effect estimates compatible with the observed data under the method used. A narrow interval indicates greater precision than a wide interval, but interpretation also depends on the scale and the clinical meaning of the differences. A p-value, when reported, assesses compatibility with a specified null hypothesis under stated assumptions; it does not measure the size or importance of an effect. Neither type of result is reported for a single primary comparison in the registry record.
The listed enrollment is 36, and the adverse-event listing reports 12 at risk in each group. These counts do not establish how many participants contributed primary-outcome measurements at each follow-up. The numbers with observed endpoint data, the handling of missing values, and the analysis population are not reported in the registry record. Without those details and the primary-outcome estimates, the posted record supports no quantitative conclusion about group differences.
9. Statistical Methods Explained
The registry characterizes the primary endpoint as a continuous measure summarized by a mean and standard deviation. In general, a mean describes the central level of scores in a group, while a standard deviation describes how dispersed individual scores are around that mean. These summaries can help readers understand the score distribution, but they do not by themselves show whether groups differ or quantify the uncertainty in a difference.
The outcome has a bounded scale: the preparation sub-scale is described as having a minimum of 5 and a maximum of 20, with higher scores indicating better preparation. Because the measure is bounded, possible score changes depend on a participant’s starting score. A mean can also conceal variation in individual responses. The registry record does not report the observed score distributions, group summaries, or whether the analysis examined assumptions relevant to the chosen statistical method.
What does randomization contribute?
In general, random assignment is intended to make treatment groups comparable with respect to both measured and unmeasured factors before the intervention. It does not guarantee balance in every realized trial, particularly when enrollment is limited. Baseline information is useful for describing the groups and judging whether any important imbalance is apparent. Baseline characteristics by group and details of the allocation procedure are not reported in the registry record.
Randomization supports a comparison of assigned groups, but it does not determine how outcomes are analyzed. An analysis may compare follow-up scores, compare changes from baseline, or model measurements over time. These approaches can estimate different quantities and rely on different assumptions. The registry lists baseline, 6 and 8 week follow-up for the primary outcome but does not report the statistical model, the principal time point, or the selected contrast.
How should repeated measurements be understood?
In general, repeated measurements from the same participant are related rather than independent. Methods that account for this within-participant relationship can use the available trajectory while recognizing that observations from one person are connected. An analysis that treats such observations as independent may understate uncertainty. The analysis method and its handling of repeated measurements are not reported in the registry record.
Missing follow-up scores can affect both the number of observations available and the validity of an estimate. In general, complete-case analysis uses participants with the required measurements, while other methods may use partial information under specified assumptions. Each approach has limitations; the assumptions matter because missingness may be related to participants’ health or responses. The number of missing primary-outcome observations and the method used to address them are not reported in the registry record.
What do uncertainty and significance measures tell readers?
In general, a confidence interval conveys uncertainty about an estimated effect and helps readers consider both its plausible size and its precision. A p-value addresses how compatible the observed data are with a stated null hypothesis under the analysis assumptions. Neither replaces the effect estimate, and neither alone establishes clinical importance. The registry record does not report a confidence interval or p-value for a single primary-outcome comparison.
When a trial includes several outcomes, time points, groups, or contrasts, the number of statistical opportunities can affect how often results appear noteworthy by chance. In general, multiplicity methods can adjust interpretation or testing to account for a prespecified family of comparisons. Whether any adjustment was applied, and which comparisons would belong to such a family, are not reported in the registry record.
What can planning calculations establish?
In general, sample-size planning asks how much information a study would need to detect a specified effect under stated assumptions. Such calculations are design illustrations, not evidence that an effect was observed, and they are not a substitute for the trial’s results. The registry’s planning assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and effects defined as fractions of an observed effect. However, the primary outcome is not reduced to one comparison across its listed categories or time points, and a single observed effect is not reported for interpreting a planning illustration. These assumptions should not be mistaken for the trial’s own design justification or for observed power.
10. Multiplicity, Missing Data and Analysis Populations
The study lists a primary preparation sub-scale and secondary outcomes of Functional Status ADL, the Center for Epidemiology Studies - Depression Scale (CES-D), and the POMS Anxiety Sub-scale. The registry lists 5 outcome measures and 10 analyses. With multiple outcomes, time points, and possible group contrasts, readers need to know which outcomes and comparisons were prespecified as primary and whether any adjustment was made for multiple testing. The multiplicity strategy and a complete prespecified analysis plan are not reported in the registry record.
The primary endpoint is listed at baseline, 6 and 8 week follow-up. The registry record does not identify a single primary time point or comparison, and its primary-outcome information is not reduced to one comparison. Without that selection, it is not possible to interpret an isolated result as the definitive primary test or to know how it relates to the other analyses.
Missing-data information is also absent. The number of participants with measured outcomes at each assessment, reasons for missingness, and methods for handling incomplete follow-up are not reported in the registry record. The record does not specify whether the primary analysis included all randomized participants, only participants with observed outcomes, or another analysis population. These details matter because the analysis population and missing-data assumptions can affect both the estimated difference and its uncertainty.
In general, multiplicity concerns false-positive findings across a family of tests, while missing-data concerns whether observed outcomes represent the randomized groups. These are distinct issues. Neither can be resolved from the outcome names and follow-up schedule alone.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Preparation and Completion | 0 | 12 | 0.0% |
| Attention Control | 1 | 12 | 8.3% |
| True Control | 0 | 12 | 0.0% |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Preparation and Completion | 0 of 12 |
| Attention Control | 0 of 12 |
| True Control | 0 of 12 |
Most frequent serious adverse event terms
| Event term | Organ system | Preparation and Completion | Attention Control | True Control |
|---|---|---|---|---|
| Death | General disorders | 0 of 12 | 1 of 12 | 0 of 12 |
Serious events with the highest arm-level rate: death (8.3%).
The adverse-event listing reports one serious event affected in the Attention Control group and none in Preparation and Completion or True Control. It lists 12 participants at risk in each group. The record also lists Death at 8.3% among the serious-event terms. Group-specific death counts are not reported in the registry record.
These figures should be read as the registry’s reported event information, not as a complete account of every possible harm or as a comparison establishing that one group is safer. A count of affected participants does not describe event timing, duration, severity beyond the serious classification, or whether an event was considered related to an intervention. Those details are not reported in the registry record.
In general, event counts from a small trial are descriptive and can be imprecise. The absence of a recorded event in a group does not establish that no risk exists, and an event in a group does not by itself establish causation. The posted information does not provide enough detail for a comparative safety analysis.
12. What the Result Does, and Does Not, Mean
The record establishes that a randomized, three-arm trial examined a facilitator-led preparation and completion intervention in people with serious illness, alongside an attention-control group and a true-control group. It identifies the preparation sub-scale of QUAL-E as the primary outcome and lists baseline, 6 and 8 week follow-up assessments. It also describes the intervention and the general nature of both comparator conditions.
The posted results do not establish whether preparation scores differed among groups, how scores changed over time, or how precisely any difference was estimated. A primary-outcome effect estimate, confidence interval, and p-value for a single comparison are not reported in the registry record. The trial’s enrollment and group counts cannot substitute for those outcome results.
In general, a randomized design can support causal comparisons when assignment, follow-up, analysis, and outcome measurement are adequately reported and handled. Randomization alone does not resolve missing data, multiplicity, measurement limitations, or uncertainty. Here, the registry does not report enough detail about those matters to assess their influence on the primary endpoint.
The endpoint is specifically preparation, a sub-scale within a broader quality-of-life measure. Any result on that scale would not automatically answer every question about overall quality of life, physical symptoms, or other domains. Nor would a group difference by itself establish that every participant experienced a similar change. The registry record supplies no outcome estimates with which to assess such possibilities.
The most defensible reading is therefore descriptive: the record documents the trial’s purpose, design, outcome definition, and limited adverse-event counts, but it does not report a quantitative primary-outcome conclusion. No claim that the intervention did or did not improve quality of life can be drawn from the information recorded.
13. Why This Trial Matters Statistically
This trial is statistically notable for its three-arm structure and repeated measurement of a bounded, continuous patient-reported outcome. The comparator choice changes the question: comparison with attention control differs from comparison with no intervention, and the attention-control comparison itself addresses a different contrast. Identifying the primary contrast before interpreting results is important, yet the registry record does not select a single primary comparison.
The baseline, 6 and 8 week follow-up schedule creates an analysis question about change over time. Repeated measurements from one participant are related, so an analysis should account for that structure. The registry record does not report the model or estimand, leaving readers unable to determine how the assessment schedule was translated into a primary statistical test.
The trial also illustrates why outcome definitions and results are both needed. The preparation sub-scale is clearly described, including its item count, range, and direction, but a measure’s definition cannot establish the magnitude or precision of an observed group difference. Without group summaries and an effect estimate, readers cannot evaluate whether any difference was small, large, or uncertain.
Finally, the listed enrollment of 36 makes transparent reporting of participant flow, observed follow-up data, and analysis populations especially useful. Such details help readers understand how much information contributes to an estimate. Those outcome-data and analysis details are not reported in the registry record, so the statistical contribution of the study remains difficult to assess from the posted results.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
A central limitation of the available record is that it does not report a single primary-outcome comparison or numerical results for the preparation sub-scale. Group means, standard deviations, effect estimates, confidence intervals, and p-values for the primary outcome are not reported in the registry record. This prevents assessment of effect direction, magnitude, and precision.
The intervention description for Preparation and Completion is incomplete: it ends while describing the second session. Although the overall purpose refers to life story, forgiveness, and future goals, the registry record does not provide a complete account of session content, facilitator procedures, or intervention adherence. The attention-control description is more specific, but the record does not report whether participants attended every meeting or completed the activities.
The registry record does not report baseline characteristics by group, participant flow through follow-up, or the number of participants contributing endpoint data at each assessment. Missing-data methods and analysis populations are also not reported. These omissions limit assessment of comparability after randomization and of possible bias from incomplete follow-up.
The trial has three groups and multiple outcomes and analyses, but the primary contrast, primary time point, and multiplicity approach are not reported in the registry record. The record does not give enough information to distinguish prespecified analyses from exploratory ones. No sample-size justification for the trial is reported in the registry record; planning assumptions associated with an illustration should not be treated as the original design rationale.
Finally, the listed adverse-event counts are limited and lack detailed descriptions, attribution, timing, and group-specific death counts. The registry status is completed, but completion status does not resolve these reporting gaps.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Outlook Quality of Life Intervention — NCT00784095.
- Registry record last updated 2016-03-22; status last verified 2016-03.
- Results first posted 2016-03-22.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT00784095, Outlook Quality of Life Intervention, is listed as a completed randomized parallel-group trial with no masking recorded. The record lists 36 participants and three groups: Preparation and Completion, Attention Control, and True Control. The study concerns people with cancer, congestive heart failure, or chronic obstructive pulmonary disease.
The primary endpoint is the QUAL-E preparation sub-scale, assessed at baseline and at 6 and 8 week follow-up. Secondary outcomes include Functional Status ADL, CES-D, and POMS Anxiety. The registry describes one serious event affected in the Attention Control group and none in the other groups; group-specific death counts are not reported.
A single primary-outcome comparison, its estimate, and its uncertainty are not reported in the registry record. Details of missing data, analysis populations, and the statistical analysis plan are also not reported.